Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Total 13F shares
-
24,415,584
-
Share change
-
-1,167,442
-
Total reported value
-
$1,642,535,471
-
Price per share
-
$67.30
-
Number of holders
-
249
-
Value change
-
-$83,041,944
-
Number of buys
-
116
-
Number of sells
-
120
Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2025
As of 31 Dec 2025,
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by
249 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,415,584 shares.
The largest 10 holders included
VANGUARD GROUP INC, UBS Group AG, CONGRESS ASSET MANAGEMENT CO, LSV ASSET MANAGEMENT, MIZUHO MARKETS AMERICAS LLC, Stephens Investment Management Group LLC, Boston Trust Walden Corp, Handelsbanken Fonder AB, Arbejdsmarkedets Tillaegspension, and Retirement Systems of Alabama.
This page lists
249
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.